Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Raymond L. Houghton is active.

Publication


Featured researches published by Raymond L. Houghton.


Oncogene | 2000

Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis.

Tongtong Wang; Deborah Hopkins; Cheryl Schmidt; Sandra Silva; Raymond L. Houghton; Hiroshi Takita; Elizabeth A. Repasky; Steven G. Reed

In order to develop effective vaccine products against human cancer, we are interested in identifying genes over-expressed in tumor cells. Through a combination of cDNA library subtraction and microarray technology, we identified seventeen genes preferentially expressed in lung squamous cell carcinoma, including four novel genes. To date, expression profiles of these genes were confirmed by Northern and/or real-time analysis, and several genes were also found to be expressed in head and neck squamous tumors. Thus, these combined methods represent a high throughput approach for identifying tumor specific genes. Furthermore, the report of characterization on these genes will allow them to be exploited for their diagnostic, prognostic, and therapeutic potentials including immunotherapy and antibody based anticancer therapy.


Clinical and Vaccine Immunology | 2002

Use of multiepitope polyproteins in serodiagnosis of active tuberculosis.

Raymond L. Houghton; Michael J. Lodes; Davin C. Dillon; Lisa D. Reynolds; Craig H. Day; Patricia D. Mcneill; Ronald C. Hendrickson; Yasir A. W. Skeiky; Diana Pedral Sampaio; Roberto Badaró; Konstantin P. Lyashchenko; Steven G. Reed

ABSTRACT Screening of genomic expression libraries from Mycobacterium tuberculosis with sera from tuberculosis (TB) patients or rabbit antiserum to M. tuberculosis led to the identification of novel antigens capable of detecting specific antibodies to M. tuberculosis. Three antigens, Mtb11 (also known as CFP-10), Mtb8, and Mtb48, were tested together with the previously reported 38-kDa protein, in an enzyme-linked immunosorbent assay (ELISA) to detect antibodies in TB patients. These four proteins were also produced as a genetically fused polyprotein, which was tested with two additional antigens, DPEP (also known as MPT32) and Mtb81. Sera from individuals with pulmonary and extrapulmonary TB, human immunodeficiency virus (HIV)-TB coinfections, and purified protein derivative (PPD)-positive and PPD-negative status with no evidence of disease were tested. In samples from HIV-negative individuals, the ELISA detected antibodies in >80% of smear-positive individuals and >60% smear-negative individuals, with a specificity of ∼98%. For this group, smears detected 81.6% but a combination of smear and ELISA had a sensitivity of ∼93%. The antigen combination detected a significant number of HIV-TB coinfections as well as antibodies in patients with extrapulmonary infections. Improved reactivity in the HIV-TB group was observed by including the antigen Mtb81 that was identified by proteomics. The data indicate that the use of multiple antigens, some of which are in a single polyprotein, can be used to facilitate the development of a highly sensitive test for M. tuberculosis antibody detection.


Oncogene | 2002

Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays

Yuqiu Jiang; Susan L. Harlocker; David A. Molesh; David C Dillon; John A. Stolk; Raymond L. Houghton; Elizabeth A. Repasky; Roberto Badaró; Steven G. Reed; Jiangchun Xu

Identifying novel and known genes that are differentially expressed in breast cancer has important implications in understanding the biology of breast tumorigenesis and developing new diagnostic and therapeutic agents. In this study we have combined two powerful technologies, PCR-based cDNA subtraction and cDNA microarray, as a high throughput methodology designed to identify cDNA clones that are breast tumor- and tissue-specific and are overexpressed in breast tumors. Approximately 2000 cDNA clones generated from the subtracted breast tumor library were arrayed on the microarray chips. The arrayed target cDNAs were then hybridized with 30 pairs of fluorescent-labeled cDNA probes generated from breast tumors and normal tissues to determine the tissue distribution and tumor specificity. cDNA clones showing overexpression in breast tumors by microarray were further analysed by DNA sequencing, GenBank and EST database searches, and quantitative real time PCR. We identified several known genes, including mammaglobin, cytokeratin 19, fibronectin, and hair-specific type II keratin, which have previously been shown to be overexpressed in breast tumors and may play an important role in the malignance of breast. We also discovered B726P which appears to be an isoform of NY-BR-1, a breast tissue-specific gene. Two additional clones discovered, B709P and GABAA receptor π subunit, were not previously described for their overexpression profile in breast tumors. Thus, combining PCR-based cDNA subtraction and cDNA microarray allowed for an efficient way to identify and validate genes with elevated mRNA expression levels in breast cancer that may potentially be involved in breast cancer progression. These differentially expressed genes may be of potential utility as therapeutic and diagnostic targets for breast cancer.


The Journal of Infectious Diseases | 1998

A Cloned Antigen (Recombinant K39) of Leishmania chagasi Diagnostic for Visceral Leishmaniasis in Human Immunodeficiency Virus Type 1 Patients and a Prognostic Indicator for Monitoring Patients Undergoing Drug Therapy

Raymond L. Houghton; Madalina Petrescu; Darin R. Benson; Yasir A. W. Skeiky; Aldo Scalone; Roberto Badaró; Steven G. Reed; Luigi Gradoni

Serologic assays using crude antigens for the diagnosis of visceral leishmaniasis in human immunodeficiency virus type 1 (HIV)-seropositive patients have been shown to lack sensitivity and specificity, particularly in AIDS patients. Antibodies to a cloned antigen, recombinant (r) K39, of Leishmania chagasi are specific for members of the Leishmania donovani complex and have been shown to indicate active disease in immunocompetent persons. This study demonstrated that antibodies to rK39 were also detectable in HIV-seropositive patients coinfected with Leishmania infantum. Furthermore, the rK39 ELISA was more sensitive than an IFA for detecting L. infantum infections in patients with AIDS. In addition, antibody titers to rK39 in HIV-negative patients infected with L. infantum or L. chagasi declined during treatment with meglumine antimoniate or liposomal amphotericin B. In contrast, most patients who clinically relapsed showed increased antibody titers to rK39. These data demonstrate the diagnostic and prognostic utility of rK39 in detecting active visceral leishmaniasis.


Clinical Cancer Research | 2005

Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer

Monica M. Reinholz; Andrea Nibbe; Leslie M. Jonart; Kathleen Kitzmann; Vera J. Suman; Janles N. Ingle; Raymond L. Houghton; Barbara K. Zehentner; Patrick C. Roche; Wilma L. Lingle

Purpose: We examined the feasibility of using molecular characterization of circulating tumor cells as a method for early detection of breast cancer. Research Design: Women without a prior history of cancer who had a breast abnormality detected on imaging followed by a breast biopsy were enrolled in this study. Density gradient centrifugation and immunomagnetic capture were used to enrich for epithelial cells from ∼20 mL of blood. Real-time reverse transcription-PCR was used to quantitate the expression levels of the highly breast-specific genes, mammaglobin, γ-aminobutyric acid type A receptor π subunit (GABA Aπ), B305D-C, and B726P in the epithelial cell–enriched samples. Results: The assay was technically feasible in 154 of 199 accrued patients. From their clinical assessment, 100 patients had benign breast disease, 10 patients had ductal carcinoma in situ, and 44 patients had invasive breast cancer. We constructed a diagnostic test that classified patients with mammaglobin levels of at least 32.2 copies/pg β-actin (units) in their circulating epithelial cells as positive for invasive breast cancer. This resulted in a sensitivity and specificity of 63.3% and 75.0%, respectively. A diagnostic test that classified patients as positive for invasive breast cancer when either mammaglobin levels were >46.3 units or B305D-C levels were >11.6 units increased the sensitivity and specificity to 70.5% and 81.0%, respectively. In the latter test, 12 of the 14 node-positive breast cancer patients were correctly identified. Including GABA Aπ and B726P in the test did not increase its diagnostic potential. Conclusions: These results suggest that molecular characterization of circulating epithelial cells using mammaglobin and B305D-C offers potential for early detection of invasive breast cancer.


The Journal of Infectious Diseases | 1999

A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera.

Raymond L. Houghton; Darin R. Benson; Lisa D. Reynolds; Patricia D. Mcneill; Paul R. Sleath; Michael J. Lodes; Yasir A. W. Skeiky; David A. Leiby; Roberto Badaró; Steven G. Reed

Peptide epitopes of Trypanosoma cruzi have been identified through expression cloning. A tripeptide (2/D/E) containing three epitopes (TcD, TcE, PEP-2) was used in ELISA to detect antibodies to T. cruzi in 239 of 240 consensus-positive sera and 41 of 42 sera confirmed positive by radioimmunoprecipitation assay. The 1 discrepant consensus-positive serum was used to expression-clone a novel gene that contained a repeat sequence. A peptide corresponding to this sequence, TcLo1.2, was specific for T. cruzi. This antigen detected the discrepant consensus-positive serum and enhanced reactivity of low-positive sera in the tripeptide assay. A branched synthetic peptide, 2/D/E/Lo1.2, or a linear recombinant, r2/D/E/Lo1.2, realized all of the diagnostic features of the four epitopes, including the ability to boost reactivity of low-reactive sera. These studies show that peptides and recombinants containing multiple repeat epitopes are powerful tools for developing assays for T. cruzi antibody detection and have direct application in blood screening.


Molecular Diagnosis | 2001

Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells.

Raymond L. Houghton; Davin C. Dillon; David A. Molesh; Barbara K. Zehentner; Jiangchun Xu; John Jiang; Cheryl Schmidt; Anthony Frudakis; Elizabeth A. Repasky; Aristides Maltez Filho; Marcos Nolasco; Roberto Badaró; Xinqun Zhang; Patrick C. Roche; David H. Persing; Steven G. Reed

AbstractBackground: We used a combination of genetic subtraction, silicon DNA micro-array analysis, and quantitative PCR to identify tissue-and tumor-specific genes as diagnostic targets for breast cancer. Methods and Results: From a large number of candidate antigens, several specific subsets of genes were identified that showed concordant and complementary expression profiles. Whereas transcriptional profiling of mammaglobin resulted in the detection of 70% of tumors in a panel of 46 primary and metastatic breast cancers, the inclusion of three additional markers resulted in detection of all 46 specimens. Immunomagnetic epithelial cell enrichment of circulating tumor cells from the peripheral blood of patients with metastatic breast cancer, coupled with RT-PCR-based amplification of breast tumor—specific transcripts, resulted in the detection of anchorage-independent tumor cells in the majority of patients with breast cancer with known metastatic disease. Conclusion: Complementation of mammaglobin with three additional genes in RT-PCR increases the detection of breast cancers in tissue and circulating tumor cells.


Transfusion | 2002

Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors

David A. Leiby; Amy P.S. Chung; Ritchard G. Cable; Jonathan Trouern‐Trend; Jeffrey McCullough; Mary J. Homer; Lisa D. Reynolds; Raymond L. Houghton; Michael J. Lodes; David H. Persing

BACKGROUND : Tick‐borne diseases, particularly babesiosis and ehrlichiosis, represent recently emerging infections. Despite an increased recognition of the threat tick‐borne agents pose to blood safety, our understanding of the prevalence and transmissibility of these agents in blood donors is limited.


Transfusion | 2005

Demonstrable parasitemia among Connecticut blood donors with antibodies to Babesia microti.

David A. Leiby; Amy P.S. Chung; Jennifer E. Gill; Raymond L. Houghton; David H. Persing; Stanley J. Badon; Ritchard G. Cable

BACKGROUND: Reports of transfusion‐transmitted Babesia microti have risen steadily during the past several years, reflecting a concurrent increase in US cases of human babesiosis. Although several studies have measured B. microti antibodies in blood donors, little is known about associated parasitemia and the inherent risk of transmitting the parasite by transfusion.


Journal of Clinical Microbiology | 2001

Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen

Michael J. Lodes; Davin C. Dillon; Raodoh Mohamath; Craig H. Day; Darin R. Benson; Lisa D. Reynolds; Patricia D. Mcneill; Diana Pedral Sampaio; Yasir A. W. Skeiky; Roberto Badaró; David H. Persing; Steven G. Reed; Raymond L. Houghton

ABSTRACT Improved diagnostics are needed for the detection ofMycobacterium tuberculosis, especially for patients with smear-negative disease. To address this problem, we have screenedM. tuberculosis (H37Rv and Erdman strains) genomic expression libraries with pooled sera from patients with extrapulmonary disease and with sera from patients with elevated reactivity withM. tuberculosis lysate. Both serum pools were reactive with clones expressing a recombinant protein referred to here as MTB48. The genomic sequence of the resulting clones was identical to that of the M. tuberculosis H37Rv isolate and showed 99% identity to the Mycobacterium bovis and M. bovis BCG isolate sequences. The genomic location of this sequence is 826 bp upstream of a region containing theesat-6 gene that is deleted in the M. bovis BCG isolate. The mtb48 1,380-bp open reading frame encodes a predicted 47.6-kDa polypeptide with no known function. Southern and Western blot analyses indicate that this sequence is present in a single copy and is conserved in the M. tuberculosis and M. bovis isolates tested but not in other mycobacterial species tested, includingMycobacterium leprae and Mycobacterium avium. In addition, the native protein was detected in the cytoplasm, as was a processed form that was also shed into the medium during culture. Serological analysis of recombinant MTB48 and theM. tuberculosis 38-kDa antigen with a panel of patient and control sera indicates that the inclusion of recombinant MTB48 in a prototype serodiagnostic test increases assay sensitivity for M. tuberculosis infection when it is combined with other known immunodominant antigens, such as the 38-kDa antigen.

Collaboration


Dive into the Raymond L. Houghton's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David H. Persing

Infectious Disease Research Institute

View shared research outputs
Top Co-Authors

Avatar

Thomas S. Vedvick

Infectious Disease Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge